Search Results
Slidesets
Cost-effectiveness of Dolutegravir in HIV-1 treatment-naïve patients in China- Yogesh Punekar
Presented at:
APACC 2018
Slidesets
O_17: Early Safety, Tolerability, and Pharmacokinetic Profile of GSK2838232, a Novel 2nd Generation HIV Maturation Inhibitor, as Assessed in Healthy Subjects- Mark Johnson, MD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Slidesets
O_10: Pharmacokinetics of Dolutegravir and Rilpivirine after Switching to the Two-Drug Regimen from an Efavirenz- or Nevirapine-Based Antiretroviral Regimen: SWORD-1/2 Pooled PK Analysis- Kimberly Adkison, PhD
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2017
Meeting Report
Meeting Report Day 1 | S. Khoo | by M. Mascolini
Presented at:
International Workshop on Clinical Pharmacology of HIV, Hepatitis and Other Antiviral Drugs 2021
Slidesets
Durability of Response After DAA Therapies - Fabien Zoulim, MD, PhD
Presented at:
International Workshop on HBV Cure 2023
Slidesets
PA6_1440_Association between non-alcohol steatohepatitis (NASH) with CI.pdf
Presented at:
APACC 2023
Slidesets
DTG versus LPV/r in second line (DAWNING): outcomes by WHO-recommended NRTI backbone- Yinzhong Shen
Presented at:
APACC 2018